Vilket är priset för PT Kalbe Farma Tbk. (KLBF)

Priset för PT Kalbe Farma Tbk. (KLBF) är $0.04784262

Vilket är marknadsvärdet för PT Kalbe Farma Tbk. (KLBF)

Marknadsvärdet för PT Kalbe Farma Tbk. (KLBF) är $2.16B

PT Kalbe Farma Tbk. (KLBF) Rörelsemarginal

PT Kalbe Farma Tbk., an Indonesian pharmaceutical leader, along with its subsidiaries, focuses on the development, manufacturing, and commercialization of pharmaceutical products across Indonesia. Its operations are structured into four primary divisions: Prescription Pharmaceuticals, Consumer Health, Nutritionals, and Distribution & Logistics. The company's diverse portfolio encompasses generic, branded, and licensed medications, including well-known names like Brainact, Cefspan, and Mycoral, which are supplied to hospitals, pharmacies, and various drugstores. Beyond prescription drugs, it offers non-prescription medicines, a range of energy and ready-to-drink beverages, dietary supplements, and other preventive health solutions. Kalbe Farma also produces specialized nutritional products tailored for all demographics, from infants to seniors, including expectant mothers and individuals with specific medical dietary needs. The firm extends contract services to other pharmaceutical companies, covering clinical study management, bioavailability/bioequivalence assessments, and analytical testing. Additionally, it provides animal health products and operates its own healthcare facilities, the Mitrasana Clinics. Its broad scope of activities further includes health screening, acting as an agent for biotechnology products, and the distribution of consumer items, medical devices, and cosmetics. The company also trades in medical and laboratory equipment and supplies, raw materials for pharmaceuticals, and consumables for hemodialysis therapy, in addition to offering advertising services. Founded in 1966, PT Kalbe Farma Tbk. is headquartered in Jakarta, Indonesia.

År	Rörelsemarginal	Ändra
Inte tillräckligt med data för de angivna datumen.

År

Rörelsemarginal

Ändra

Inte tillräckligt med data för de angivna datumen.

Företag	Rörelsemarginal	Skillnad i rörelsemarginal	Land
Eli Lilly and Company LLY.US	43.92%	-	US
Johnson & Johnson JNJ.US	26.81%	-	US
AbbVie Inc. ABBV.US	29.32%	-	US
Roche Holding AG RO.SW	26.59%	-	CH
Merck & Co., Inc. MRK.US	16.65%	-	US

Företag

Rörelsemarginal

Skillnad i rörelsemarginal

Land